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Abstract
Background:  Concerns regarding the use of antipsychotic medication in secondary care suggested an
examination of primary care prescribing.
Aim: To audit and intervene in the suboptimal prescribing of antipsychotic drugs to primary care patients.
Design of study: Cross-sectional prevalence: subsequent open treatment intervention.
Setting: Seven of the 29 practices in the Eastern Hull Primary Care Trust.
Methods: Criteria for best practice were developed, against which prescribing standards were tested via audit.
Patients identified as suboptimally prescribed for were invited to attend an expert review for intervention.
Results: 1 in 100 of 53,000 patients was prescribed antipsychotic treatment. Diagnoses indicating this were
impossible to ascertain reliably. Half the regimes failed one or more audit criteria, leaving diagnosis aside. Few
practices agreed to patients being approached: of 179 invitations sent, only 40 patients attended. Of 32 still taking
an antipsychotic drug, 26 required changes. Mean audit criteria failed were 3.4, lack of psychotic disorder diagnosis
and problematic side effects being most frequent. Changes were fully implemented in only 16 patients: reasons
for complete or partial failure to implement recommendations included the wishes or inaction of patients and
professionals, and worsening of symptoms including two cases of antipsychotic withdrawal syndrome.
Conclusion:  Primary care prescribing of antipsychotic drugs is infrequent, but most is unsatisfactory.
Intervention is hampered by pluralistic reluctance: even with expert guidance, rationalisation is not without risk.
Use of antipsychotic drugs in primary care patients whose diagnosis does not warrant this should be avoided.
How this fits in: This study adds to concerns regarding high levels of off-licence use of potentially harmful
medication. It adds evidence of major difficulties in rationalizing suboptimal regimes despite expert input.
Relevance to the clinician is that it is better to avoid such regimes in the first place especially if there is no clear
'exit strategy': if in doubt, seek a specialist opinion.
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Introduction
We have previously published on the utilization of high
dose antipsychotic treatment and polypharmacy in sec-
ondary care, and lack of adherence to appropriate guide-
lines [25]. The publication of NICE guidance on
antipsychotic treatment in schizophrenia [4] would, we
assumed, result in positive changes in secondary care pre-
scribing. This guidance recommended atypical antipsy-
chotic drugs in many common clinical situations,
including for new patients, relapsing patients and symp-
tomatically well controlled patients if side effects were
unacceptable: polypharmacy and high doses were advised
against.
Given the unsatisfactory state of secondary care prescrib-
ing demonstrated by our first study, we considered that
the situation in primary care may benefit from examina-
tion particularly in the context of NICE. We therefore set
up a further audit to identify patients of general practi-
tioners receiving potentially problematic antipsychotic
regimes, with a subsequent optional intervention to be
offered to these GPs and their patients to rationalize their
medication. The overall aim was to improve the wellbeing
of a large number of patients currently receiving antipsy-
chotic treatment sub-optimally. Optimizing such medica-
tion regimes should, we anticipated, have the effect of
minimizing symptoms and side effects while maximizing
quality of life.
The Eastern Hull Primary Care Trust (PCT) agreed to sup-
port the audit. This PCT has a catchment population of
125,000, with a typical range of urban inner-city health &
social problems. It comprises 29 practices including 57
GPs, 17 of them single handed. There were at the time of
the audit 12 community pharmacists working with 23 of
the practices, offering hands-on prescribing support. From
2000 to 2003, the total number of prescriptions for antip-
sychotic drugs in Eastern Hull PCT rose moderately from
12117 to 12703 per year: however their cost rose mark-
edly, from £215,752 to £324,511. While the usage and
cost of conventional and depot medications remained
constant, the usage and cost of atypical antipsychotic
drugs, particularly olanzapine and risperidone, increased
substantially.
Method
The following audit criteria were adopted to define possi-
ble suboptimal prescribing in the patient group. They
were derived from the literature, and a process of discus-
sion and consensus finding between the four authors.
1. On thioridazine [22]
2. On more than one antipsychotic drug [4]
3. Psychotropic polypharmacy (increased risks of side
effects and interactions: evidence in support of efficacy
unclear in many diagnostic categories)
4. Greater than recommended maintenance dose [4]
5. Dose less than a quarter of recommended maintenance
dose (therefore dubious efficacy)
6. No current diagnosis indicating an antipsychotic i.e.
psychosis or short-term behavioural disturbance [3]
7. Long term anticholinergic treatment [27]
8. Not reviewed by GP or psychiatrist for 1 year
9. Unresolved problematic symptoms
10. Unresolved problematic side effects
Community pharmacists working in GP practices
attended a training session about the project and the audit
criteria, run by AM and a research nurse. They then
audited all patients prescribed any antipsychotic medica-
tion in 7 of the 29 practices in Eastern Hull PCT. Patients
were identified through electronic patient records systems
at the surgeries. Audit criteria for identified patients were
checked using electronic records, longhand records and
personal enquiry of the GP if necessary.
For the subsequent intervention study, GPs were asked for
permission to invite patients identified as failing any audit
criteria for an appointment with AM and CS. Participating
surgeries were provided with the text of an invitation let-
ter, to be printed out on surgery notepaper and sent to eli-
gible patients by practice staff: this preserved patient
anonymity. GPs were offered advice regarding their
patients who failed to respond or refused to be seen.
Patients agreeing to a review were notified to CS, who sub-
sequently attended the surgery to examine their notes and
summarized their history prior to an appointment with
AM and CS. Patients were seen at the surgery or, if they
preferred, at their home. When seen, patients were asked
to provide written consent for AM and CS to administer
ratings of symptoms, side effects, general function and
quality of life. The current medication regime and the
patients' general mental health and well-being were then
discussed. Proposed changes in medication, if any, were
shared with the patient, and written advice on those
agreed was given. Patients were informed that a follow-up
appointment would be sent to assess progress once the
changes had been implemented. The GP was informed in
writing of the evaluation, and asked to implement the rec-
ommendations regarding medication changes.Annals of General Psychiatry 2005, 4:18 http://www.annals-general-psychiatry.com/content/4/1/18
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Symptoms were rated with the Brief Psychiatric Rating
Scale (BPRS), which identifies a broad spectrum of psy-
chopathology across diagnostic groupings [20]. Antipsy-
chotic side effects were measured with the Abnormal
Involuntary Movements Scale (AIMS) [2] which assesses
Parkinsonism, dyskinesia and akathisia. Side effects were
also enquired about in general terms with each patient.
General function was assessed using the Global Assess-
ment of Function (GAF) [9] and the Clinical Global
Impression (CGI) [1]. Quality of life was measured with
the Quality of Life Self-Assessment Scale (QLSAS) [24].
Basic demographic and clinical data were collected: age,
sex and clinical diagnosis from GP notes and the inter-
view. At follow-up after a clinically appropriate period,
patients' general mental health was reviewed and their
medication noted: the rating scales were repeated. Non-
parametric Wilcoxon signed ranks tests were carried out in
order to ascertain whether changes in medication were
associated with any significant changes in rating scale
scores.
Results
Almost 53,000 general practice patients were screened by
the community pharmacists: 1% were prescribed antipsy-
chotic drugs. The most frequent reasons for audit criterion
failure were psychotropic polypharmacy and chronic anti-
cholinergic treatment. However, community pharmacists
reported insurmountable difficulty in establishing the
diagnosis of patients prescribed antipsychotic drugs by
their GPs even when case notes were scrutinized and per-
sonal enquiries made of the GPs. This criterion therefore
had to be abandoned as the majority of those prescribed
antipsychotic treatment would have failed it. Similar cave-
ats applied to the criteria regarding unresolved symptoms
and side effects: no figures were returned, although all
these criteria were examined in patients presenting for the
Failure of Audit Criteria Figure 1
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subsequent intervention. Excluding unfeasible criteria,
overall 280 i.e. just over half the patients were being pre-
scribed regimes of medications which failed one or more
audit criteria.
A minority of practices accepted the opportunity for
review of their patients. 179 invitations to patients were
sent: only 74 replies were received. We were informed
later that 13 of the patients resided in a single nursing
home: none replied. 54 patients accepted an appointment
to be seen: 14 failed to attend, leaving 40 patients who
underwent at least an initial evaluation. This represented
only 23% of the number eligible for a review, whose GPs
had agreed to their being approached.
The mean age of the patients was 59 years, with a range of
62 years: the oldest patient was 95 and the youngest
patient was 33. 15 patients were men and 25 were
women: there were no significant sex differences in age or
any rating scale scores either initially or at follow-up. The
diagnoses of these patients indicated that most were being
prescribed antipsychotic medication off license. Clinically
the diagnoses included 12 patients with uni-polar depres-
sion, 8 with learning disability, 6 with schizophrenia, 4
with anxiety or panic disorder and 3 with vertigo: 1 each
dementia, personality disorder, bipolar disorder, alcohol
dependence, obsessive-compulsive disorder and restless
legs. In one patient no formal diagnosis could be arrived
at even after careful scrutiny of her history and two per-
sonal interviews with both the patient and her mother.
32 patients were still taking antipsychotic treatment when
seen. Figure 1 demonstrates the pattern of failure of audit
criteria of these patients: our investigations revealed that 5
of the 29 with no formal psychotic disorder diagnosis did
in fact have convincing evidence of psychotic symptoms
either previously or currently. All the patients on more
than one antipsychotic drug were diagnosed with schizo-
phrenia. The mean number of criteria failed per patient
was 3.4, with a range of 1–6: the standard deviation was
1.2.
Only 8 (25%) of the patients were prescribed atypical
drugs, the rest were prescribed conventional treatment.
Clinical actions were recommended for 26 out of the 32
patients remaining on antipsychotic treatment at the time
of interview. In half of the patients [15], stopping antipsy-
chotic treatment altogether was advised. All 11 patients
taking anticholinergic drugs on a chronic basis were
advised to cease them. Other psychotropic drugs were sug-
gested to be discontinued in 8 patients, some of whom
had already stopped antipsychotic treatment before the
first interview. In only 5 of the 32 patients was an atypical
antipsychotic treatment recommended instead of existing
conventional treatment.
Rating scale scores demonstrated that the 26 patients
whose prescribing required amendment were minimally
or mildly symptomatic for the most part. However they
had a significant burden of motor side effects, and their
function was far from optimal (see Table 3). Patients expe-
rienced great difficulty in filling in the QLSAS: this scale
comprises a comprehensive list pertaining to life in gen-
eral e.g. utilities, housing, access to leisure etc. Patients
were asked to mark items with which they were not satis-
fied. Patients did not appear to relate well to the items as
stated, and frequently tried to mark all which were satis-
factory, becoming confused when directed not to. This
difficulty was not compensated for by the QLSAS's free-
dom from mood and side effect items, and its use had to
be dispensed with.
BPRS symptoms scores at second interview had improved
to a statistically but not clinically significant degree. AIMS
side effects scores had reduced significantly: CGI and GAS
scores were improved, but this was not statistically signif-
icant. Although all 24 patients who attended follow-up
were included in the analysis, a third, i.e. 8 patients had
not altered their medication as advised, either partially or
at all. 4 patients unfortunately felt worse on their new
regimes than previously, and had reverted to their former
prescriptions. These included 2 patients with definite and
unpleasant conventional antipsychotic withdrawal syn-
dromes. One patient decided herself not to make the
changes after considering what had been advised: the CPN
of another patient appeared to be the deciding factor in
the continuation of the patient's suboptimal treatment,
Table 2: Patients failing single or multiple audit criteria: 'no 
positive diagnosis' excluded
Failing one criterion 39%
Failing two criteria 11%
Failing three criteria 4%
Failing 4 or more criteria 0.2%
Total failing one or more 52.4%
Table 1: Patients prescribed antipsychotic drugs in 7 practices in 
East Hull: failure of individual audit criteria
Total number of patients audited 52885 %
Patients prescribed antipsychotic drugs 534 1.01
Prescribed droperidol 0 0
Prescribed thioridazine 18 3.8
>1 antipsychotic 32 5.9
Antipsychotic + other psychotropic 172 32.2
No positive diagnosis 46 8.6
Anticholinergic drugs >3 months 64 12.0
Not reviewed within 12 months 16 3.0Annals of General Psychiatry 2005, 4:18 http://www.annals-general-psychiatry.com/content/4/1/18
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citing the consequences of relapse. In two patients the GP
and consultant failed to alter the prescription for reasons
of oversight.
Illustrative cases
1 A 63 year old man with a 20 year history of chronic
depression subsequent to a road accident (which caused
several hours' loss of consciousness) and a one year his-
tory of epilepsy. He had mild depressive symptoms but no
psychotic symptoms at any point. He was taking 75 mg
chlorpromazine, 10 mg amitriptyline (originally for head-
ache) and 5 mg nitrazepam daily. He had a marked
tremor and complained of restlessness. He was advised to
reduce and stop the chlorpromazine over six weeks on the
grounds of tremor, probable akathisia, depressogenic and
theoretical epileptogenic effects. When reviewed three
months later, the patient described a severe exacerbation
of restlessness, feeling hot, cold and sweating during his
dosage reduction, to the point where his GP was obliged
to reinstate the original dose. The patient's GP had substi-
tuted citalopram 20 mg for the 10 mg amitriptyline at our
suggestion. The patient reported feeling more relaxed on
this regime and furthermore had been able to stop using
codeine for his headaches and laxatives for his previous
constipation subsequent to codeine.
2 A 73 year old lady with diagnoses of mild learning diffi-
culties and bipolar affective disorder, stable for the last
three years and living in a nursing home. She was taking
carbamazepine 300 mg bd, risperidone 2 mg bd, paroxet-
ine 20 mg bd, and thyroxine. She was grossly obese with
a BMI of 40, suffered from osteoarthritis and walked with
a Zimmer frame. She also suffered from Parkinsonism and
osteoporosis. We advised gradual alterations culminating
in valproate semi-sodium as mood stabilising mono-ther-
apy only. The grounds for this were the lack of tolerability
and poor efficacy of carbamazepine compared to val-
proate semi-sodium, its induction of enzymes reducing
antipsychotic levels, the mutually antagonistic effects of
risperidone and paroxetine on mood, the side effects of
Parkinsonism of both risperidone and paroxetine, and the
side effects of hyperprolactinaemia, which can exacerbate
osteoporosis, and weight gain of risperidone. At review
two months later, no changes of any kind had been imple-
mented. Following discussions amongst the treating team
it was decided "the community nurse thinks there should
be no changes to her medication as over the last 3–4 years
she has been stable...she is 73 years old and not a young
woman"
3 A 59 year old man with bipolar affective disorder and a
recent TIA, taking 700 mg lithium daily (level 0.9), chlo-
rpromazine 300 mg daily and 10 mg procyclidine daily.
He complained of anxiety symptoms, restlessness and a
tremor of several months' duration. He was advised to
reduce and stop his chlorpromazine and procyclidine
over a three month period, and reduce the dose of lithium
to 600 mg daily. At review the patient had successfully
stopped these medications and his tremor was much
reduced. His GP had started a small dose of buspirone,
and his anxiety and general mood were much improved.
He was much more socially active and was attending fur-
ther education.
4 A 55 year old lady, the wife of patient 3 above. Her GP
referred her with addiction to sleeping tablets and men-
tioned that she stayed in bed all day. She was taking chlo-
rpromazine 300 mg, stopped two weeks before being seen
by ourselves, as she had begun to complain of worsening
tremor, but when seen was still taking procyclidine 10 mg
daily. At interview the patient gave a four year history of
chronic anxiety and depression previous to which she had
probably been dependent on alcohol for 11 years, con-
suming 70 units per week. Her depressive symptoms
approached psychotic intensity and in addition she had
orofacial dyskinesia. She was advised to stop procyclidine
and to commence venlafaxine up to 225 mg daily: she had
failed to respond to SSRIs previously. When seen four
months later, the patient's husband said she was like a dif-
ferent woman: her depression had almost completely
Table 3: Rating scale scores at each interview, changes and significance over time
Initial interview: n = 26 Follow-up interview: n = 24 p
Mean score range Sd Mean score range sd
B P R S 71 – 1 7 450 – 1 2 30 . 0 0 6
CGI 2.8 0–6 1.4 2.6 1–6 1.3 ns
AIMS 10 0–39 10 7 0–27 7 0.001
GAS 61 10–93 22 66 15–95 20 ns
BPRS – Brief Psychiatric Rating Scale
CGI – Clinical Global Impression
AIMS – Abnormal Involuntary Movements Scale
GAS – Global Assessment ScheduleAnnals of General Psychiatry 2005, 4:18 http://www.annals-general-psychiatry.com/content/4/1/18
Page 6 of 8
(page number not for citation purposes)
resolved, she was attending further education and had
managed to give up smoking. Her GP had added a small
dose of buspirone to her venlafaxine. She had successfully
stopped her procyclidine and had no orofacial dyskinesia.
5 A 34 year old man with schizophrenia taking 10 mg ris-
peridone daily i.e. greater than the recommended dose,
and fluoxetine 20 mg daily: no indication for fluoxetine
could be established. The patient had a BMI of 36 along-
side poorly controlled positive symptoms, negative symp-
toms which had led to his losing his employment, and
side effects of restlessness, gastrointestinal disturbance,
blurred vision and abnormal involuntary movements
alongside marked weight gain. The patient was advised to
stop fluoxetine which was thought to be exacerbating his
positive symptoms and abnormal movements, and
responsible for gastro-intestinal disturbance. He was
advised to substitute amisulpride at the low dose of 300
mg daily for the large dose of risperidone: this drug is
associated with very little weight gain and is very effective
for negative symptoms at such low doses, while maintain-
ing efficacy for positive symptoms. At review the patient
was taking 200 mg of amisulpride daily: his positive and
negative symptoms were much improved, he was much
more active and no longer complained of abnormal
movements or gastro-intestinal disturbance. In addition,
he reported much better memory and concentration.
6 A 73 year old lady taking venlafaxine 150 mg daily and
5 mg olanzapine at night. She had a history of recurrent
depression but never any psychotic symptoms. Three
years previously a consultant psychiatrist had advised
reduction of the antipsychotic drug but this had not been
implemented. The patient was not depressed at all but
complained of having gained at least 7 lb weight on olan-
zapine: her BMI was 26. She was advised to stop this drug.
At review four months later, the patient had stopped the
olanzapine successfully: she had lost 7 lb in weight, and
her BMI was 24. Furthermore the patient felt her energy
levels were significantly improved, with less sedation and
more capacity for physical activity.
Discussion
Antipsychotic prescription is not rare in primary care
patients: furthermore in this study over half was poten-
tially problematic in terms of accepted prescribing stand-
ards, leaving aside the lack of diagnostic justification
available in GP records. The situation in secondary care
has been investigated using suboptimal prescribing crite-
ria not dissimilar to our own [19]. It was found that nearly
46% of regimes were suboptimal: greater consultant con-
tact was associated with better prescribing practice. These
authors concluded that prescribing practices in real-world
settings frequently deviated from evidence-based guide-
lines. We would add that this deviation may be substan-
tially more extensive in primary and general secondary
care compared to specialist secondary care, and would
tentatively assume that the lack of consultant psychiatrist
input may be a factor here. For instance another primary
care audit of 170 patients prescribed atypical antipsychot-
ics drugs found nearly all were subject to psychotropic
polypharmacy, over a third had no licensed indication,
30% were over 75 years old, only half were monitored six
monthly or more: half had not seen a consultant [6]. A
population based observational study in primary care
demonstrated a 16% increase in the use of antipsychotic
drugs over a decade [14]. More than half of all first-time
use was for depression, panic and anxiety disorder with
less than 10% for psychosis: thioridazine, which was vir-
tually withdrawn shortly after this study ended in 2000,
was most commonly prescribed throughout.
Further research on atypical antipsychotic drug prescrib-
ing trends in primary care found a six-fold increase in five
years in the West Midlands: rates of use varied three-fold
within the region even when local population need was
accounted for. In generalist secondary care medicine in
Germany, it has been shown that a minority of prescrip-
tions for antipsychotic drugs were for indications of psy-
chosis, over half were for patients age 65 or older, and
only 40% were given by psychiatrists: the rates of prescrip-
tion had risen in parallel with a decrease in prescribing
benzodiazepines [16].
A recent study of one sixth of the population of Italy
reported that one in 50 elderly people were prescribed
antipsychotic drugs during a single year, two-thirds being
conventional drugs [21]. In nursing homes in the USA,
27.6% of residents were given antipsychotic treatment in
2000–2001: less than half received treatment following
appropriate guidelines, and its effectiveness did not differ
whether guidelines were followed or not [5]. A further
German study [11] demonstrated that 6% of a population
of 25 million were prescribed antipsychotic drugs at least
once within a two and a half year period: again, most pre-
scriptions were for conventional antipsychotic drugs, writ-
ten by non-specialists. These authors expressed concern
regarding the high frequency of psychotropic polyphar-
macy, and co-prescription of cardiovascular and meta-
bolic treatments. Some of the atypical antipsychotic drugs
may be particularly associated with cardiac and metabolic
side effects.
A French utilization study has confirmed high rates of psy-
chotropic polypharmacy alongside antipsychotic treat-
ment, despite lack of evidence for the efficacy of such
combinations [17]. By contrast, a study of private psychi-
atric practice in Switzerland demonstrated strong adher-
ence to international guidelines, with low use ofAnnals of General Psychiatry 2005, 4:18 http://www.annals-general-psychiatry.com/content/4/1/18
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antipsychotic polypharmacy and psychotropic comedica-
tion [23].
There is no shortage of material advising against the prac-
tices which we, and others in the field, have encountered.
Patients without schizophrenia and the elderly may be
particularly liable to serious side effects of antipsychotic
drugs [8]. Antipsychotic polypharmacy cannot be gener-
ally recommended, even in schizophrenia, because of lack
of efficacy [13]: furthermore, it is associated with greater
use of anticholinergic and benzodiazepine drugs [12].
Unlicensed prescribing of antipsychotics in dementia is
not recommended: their use is associated with a threefold
increased risk of serious cerebral cerebrovascular events
[7]. It has been known for many years that non-psychotic
subjects acutely exposed to conventional antipsychotic
drugs may suffer persistent adverse effects, including dys-
phoria (subjectively unpleasant mood) for several weeks
[15].
The patients in our study were not particularly sympto-
matic but were middle aged/elderly, and had a significant
burden of motor side effects. Our patients' experience of
worsening of symptoms and antipsychotic withdrawal
syndromes is of particular concern. Re-emergence of
symptoms for which the drug was originally prescribed
has been described previously in a learning disabled pop-
ulation who discontinued thioridazine [18]. Deteriora-
tion was associated with longer period of treatment, and
occurred regardless of whether the thioridazine was
replaced with another antipsychotic drug.
More recent work has highlighted the gap between guide-
lines and utilization in the real world [26]. Economic and
social conditions, specifically rapidly increasing economic
growth, may be associated with rapidly increasing drug
consumption [10]. If psychotropic medications are being
prescribed for symptoms such as depression, insomnia
and anxiety, which can be attributed as much or more to
social and personal problems rather than genuine illness,
doctors are in effect providing a medical solution where
none is indicated. This excessive reliance on pharmaco-
therapy may bring with it irrational combinations of
drugs in inadequate doses for long periods: clearly con-
trary to the principles of rational evidence based therapy.
Our limited results suggest stopping redundant antipsy-
chotics reduces side effect burden. However, getting these
patients seen, and implementing change, is very difficult
indeed and not entirely without risk to patients' wellbe-
ing. The obvious conclusion to be drawn is that the pre-
scription of antipsychotic drugs, particularly in the long
term, should be avoided in patients in whom these drugs
are not indicated, or in whom benefits are likely to be
marginal.
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